B-Cell Chronic Lymphocytic Leukemia Completed Phase 1 Trials for Ibrutinib (DB09053)

Also known as: B-cell Chronic Lymphocytic Leukemia / Chronic lymphocytic leukemia / Leukemia lymphocytic chronic / CLL / Chronic lymphoid leukaemia / Lymphoid leukaemia, chronic / Lymphoid leukemia, chronic / Chronic lymphatic leukaemia / Chronic lymphoid leukemia / Leukaemia lymphocytic chronic / Chronic lymphatic leukemia / Chronic lymphocytic leukaemia NOS / Leukaemias chronic lymphocytic / Chronic lymphocytic leukaemia / Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoplasmacytic leukemia / B-cell chronic lymphocytic leukaemia

IndicationStatusPhase
DBCOND0030547 (B-Cell Chronic Lymphocytic Leukemia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02381080Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyTreatment
NCT01292135Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)Treatment